Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (June 2008)
26 slides from Lisata Therapeutics's investor presentation, Jun 26, 2008
Slide 1: Investor Overview
NeoStem~ TF, Investor Overview Robin Smith, MD, MBA CEO and Chairman of the Board (AMEX: NBS)
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business,
Slide 3: NeoStem
NeoStem Listed on the American Stock Exchange (ticker: NBS) Have completed approximately $13 Million in financing through May 2008 NeoStem is pursuing three integrated business strategies — Autologous Adult Stem Cell Collection, Processing and Storage Domestic and Abroad — Autologous Adult Stem Cell
Slide 4: Company Overview
Company Overview* NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered the research an
Slide 5: Company Highlights
Company Highlights Multiple revenue streams through patient collection fees, processing center collection fees, and storage fees, which represent recurring revenue Cumulative recurring revenue stream from storage fees could mean base of 5,000 patients yields approximately $2 million per year in EBIT
Slide 6: Adult Stem Cell Collection
Adult Stem Cell Collection = NeoStem has created a safe and minimally invasive way for adults to have their stem cells collected today and stored for future use NeoStem’s platform enables doctors and patients ready access to their cells as the therapies become available in the future Collecting Own
Slide 7: 70+ Diseases Treated w/Stem Cells
70+ Diseases Treated w/Stem Cells Results for many have been quite encouraging Heart Disease “It saved my life... my own stem cells.” BERNIE Adult Stem Cell Heart Recipient Lupus “My Lupus has been in remission for more than 5 years.” KatHy ‘Adult Stem Cell Recipient Hi Multiple Sclerosis “Stem Cell
Slide 8: Adult Stem Cells are in the news...
Adult Stem Cells are in the news...
Slide 9: Bernard van Zyl - Congestive Heart Failure
Bernard van Zyl 72 years old Congestive Heart Failure
Slide 10: Virtually All Therapeutic Areas
Virtually All Therapeutic Areas Over 2000 Adult Stem Cell Clinical Trials Over 500 Specific to Autologous Use + By 2009, it is forecasted the first autologous products will be on the market in both orthopaedic and cardiovascular markets.* + By 2017, it is forecasted that a minimum of 16 stem cells p
Slide 11: Projected Stem Cell Therapy Sales
Projected Stem Cell Therapy Sales $9,000,000 $8,000,000 % $7,000,000 o ‘66 $6,000,000 n — $5,000,000 I 354,000,000 c $3,000,000 $2,000,000 $1,000,000 so $8.538 Billion in U.S. by 2017 Stem Cell Therapy: ‘$7,045,508 A $20 billion worldwide market by 2010 eats —-Frost & Sullivan $3,069,764 $4,611,448
Slide 12: Clinical Trials in Cardiovascular Disease
There are over 450 Clinical Trials in Cardiovascular Disease One Indication Only Institution Location No. Condition Length of Sub. Study Helsinki University Finland 60 Heart Failure 2006-2009 Texas Heart Institute Houston 60 CAD 2006-2008 Rigshospitalet 40 Atherosclerosis 2005-2009 Copenhagen Minnea
Slide 13: Milestones
Milestones Signing three new collection center agreements: New York City, LA Area, Miami Recently launched Long Island, New York facility with 100 physician practice, ProHealth Executed collaborative agreement with New England Cryogenic Center, one of the largest cryopreservation facilities in the c
Slide 14: Our Revenue Model
Our Revenue Model * Current: Collection center fees Collection from patients Processing patient cells Storage (recurring revenue) Usage Fees + Potential: Supplier of stem cells for research Collection fees for trials Government/military contracts SBIR grants Licensing of technology Medical Tourism 1
Slide 15: Disclaimer: Slide is for Demonstration Purposes Only
Disclaimer: Slide is for Demonstration Purposes Only EBIT SENSITIVITY Includes annual storage $8,000,000 $6,000,000 Breakeven Point (drops by 285. collections per each 1,000 storage $4,000,000 | CF ts — $2,000,000 Overhead $3,000,000 — $3,500,000 + $4,000,000 PP eS (2.000.000) (4.000.000) _— 6,000,0
Slide 16: Exclusive World Wide VSEL License
Exclusive World Wide VSEL License Very Small Embryonic-Like (VSELs) Stem Cells + Each of us has a population of very primitive embryonic like stem cells that have remained dormant in our bodies since birth — Can be mobilized in the blood using NeoStem Process — Should be easily recovered — Cryoprese
Slide 17: Very-Small Embryonic-like Stem Cells (VSELs)
Very-Small Embryonic-like Stem Cells (VSELs) VSELs 2um pancreas
Slide 18: Morphological and molecular characterization of VSELs
Leukemia (2006), 1-7 Morphological and molecular characterization of novel population of CXCR4 * SSEA-4 * Oct-4* very small embryonic-like cells purified from human cord blood — preliminary report M Kucia!, M Halasa®, M Wysoczynski', M Baskiewicz-Masiuk?, $ Moldenhawer', E Zuba-Surma!, R Czajka?, W
Slide 19: Translational Programs
Translational Programs Dr. Roberto Bolli -Chairman, Dept of Cardiology, UofL -Transplantation of bone-marrow derived VSELs attenuates LV Dysfunction and remodeling after MI (Stem Cells (in press)). AHA ‘07 Dr. Janina Ratajezak, SCI, UofL — In vivo evidence that CD45(-) VSELs differentiate into CD45(
Slide 20: Intellectual Property
Intellectual Property + 4 Patent Applications Pending on Platform Business: - Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual — Process by which NeoStem prepares and stores stem cells collected from peripheral blo
Slide 21: Scientific Advisory Board
Scientific Advisory Board Wayne A. Marasco, M.D., Ph.D. Chairman - Chairman of Scientific Advisory Board. Associate Professor- Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the lead in expand
Slide 22: Advisory Board
Advisory Board hysicians (FACEP) . in the world to ig Medicine. A graduate of Columbia University, College of el + Ron Rothenberg MD, FACEP.- Dr. Rothenberg is a Fellow of the American College of Emergency Pi and is the founder of the California HealthSpan Institute in Encinitas, California. He was
Slide 23: Capitalization
Capitalization At June 19, 2008 Shares Common Stock 5,903,930 Stock Options 1,803,300 Weighted average exercise price = $4.00 Warrants 2,893,397 Weighted average exercise price = $5.46 Fully Diluted Ownership 10,600,627 NBS Price Per Share $.90 Market Capitalization $5.31 million Stock Symbol (AMEX)
Slide 24: Investment Considerations
Investment Considerations Exponential potential earnings leverage with small number of physicians joining network (approximately 200) + 1 collection per month minimum from each physician is projected to yield approximately $20,000 per year to EBIT, 5 collections per month is projected to yield appro
Slide 25: Peer Valuation Comparison
Varos Shae mrlet_—Emterprie, © uTM— lt Capy compa my Teter rie cap ‘alue rev rev ewes Ineostem es Samo 8 78 $ 53 $08 ma 525 kattaterh cueob ono oa he a2 03 oa foord ood america cealab ome 25 23 6a oa aa leryocelt ir ccatob oso 98 as ars os 03 fvece (Pi pursed) ase 7z0 3000 200 ero as 38 |sdvanadcel'
Slide 26: Contact Information
Contact Information Robin Smith, MD MBA Chairman & CEO Direct: (212) 584-4174 Email: rsmith@neostem.com NeoStem, Inc. 420 Lexington Avenue Suite 450 New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK 24